NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) E
Post# of 112
(Total Views: 104)
Posted On: 04/02/2024 4:55:27 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares of Appili. Assets acquired by Aditxt will include FDA-approved LIKMEZ(TM), which is the ATI-1701 tularemia vaccine defense program, and the ATI-1801 topical formulation. “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact. The urgency for innovative and effective public-health solutions is unprecedented. The need to discover and bring new treatments to the market or to enhance existing ones to combat public-health challenges has never been more critical. By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefense domain, Aditxt can substantially contribute to advancing public-health solutions.”
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares of Appili. Assets acquired by Aditxt will include FDA-approved LIKMEZ(TM), which is the ATI-1701 tularemia vaccine defense program, and the ATI-1801 topical formulation. “The acquisition of Appili would represent another step in Aditxt’s journey towards advancing promising innovations in health,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “Our mission is to accelerate some of the most promising health innovations, like those developed by Appili, to reach their full potential and to have a lasting impact. The urgency for innovative and effective public-health solutions is unprecedented. The need to discover and bring new treatments to the market or to enhance existing ones to combat public-health challenges has never been more critical. By integrating Appili’s proven expertise and diverse portfolio in the infectious disease and biodefense domain, Aditxt can substantially contribute to advancing public-health solutions.”
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)